Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more) This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Hikma Pharmaceuticals Plc (PK) HKMPF

Alternate Symbol(s):  HKMPY

Healthcare Drug Manufacturers - Specialty & Generic
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:HKMPF)

Hikma launches TYZAVAN(TM) (vancomycin injection, USP) in the US

PR Newswire December 8, 2025

Hikma receives FDA approval for TYZAVAN(TM) (Vancomycin Injection, USP) in the US

PR Newswire July 2, 2025

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

PR Newswire June 28, 2025

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

PR Newswire May 27, 2025

Hikma acquires Novugen's FDA-approved ANDA for trametinib

PR Newswire April 17, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

GlobeNewswire March 20, 2025

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

PR Newswire January 14, 2025

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

PR Newswire August 20, 2024

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

PR Newswire August 15, 2024
View More News ››

Opinion & Analysis (PINL:HKMPF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:HKMPF)

Opioids Market Size, Share, Trends and Forecast 2022-2027

According to IMARC Group’s latest report, titled “Opioids Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...
edwardebreen15 - August 23, 2022
View more Bullboard ››

US Energy Corp

US Energy Corp

U.S. Energy Corp., an independent energy company, focuses on the acquisition, exploration, and development of industrial gas, ...
View More »

Podcasts